These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37162954)

  • 1. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
    Hurrish KH; Su Y; Patel S; Ramage CL; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
    Res Sq; 2023 Apr; ():. PubMed ID: 37162954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
    Hurrish KH; Su Y; Patel S; Ramage CL; Zhao J; Temby BR; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
    Biochem Pharmacol; 2024 Feb; 220():115981. PubMed ID: 38081370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
    Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
    J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
    Wu S; Liu F; Gai Y; Carter J; Edwards H; Hüttemann M; Wang G; Li C; Taub JW; Wang Y; Ge Y
    Leuk Res; 2024 Sep; 144():107547. PubMed ID: 38968731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
    Hege Hurrish K; Qiao X; Li X; Su Y; Carter J; Ma J; Kalpage HA; Hüttemann M; Edwards H; Wang G; Kim S; Dombkowski A; Bao X; Li J; Taub JW; Ge Y
    Biochem Pharmacol; 2022 Nov; 205():115283. PubMed ID: 36208684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
    Bosc C; Saland E; Bousard A; Gadaud N; Sabatier M; Cognet G; Farge T; Boet E; Gotanègre M; Aroua N; Mouchel PL; Polley N; Larrue C; Kaphan E; Picard M; Sahal A; Jarrou L; Tosolini M; Rambow F; Cabon F; Nicot N; Poillet-Perez L; Wang Y; Su X; Fovez Q; Kluza J; Argüello RJ; Mazzotti C; Avet-Loiseau H; Vergez F; Tamburini J; Fournié JJ; Tiong IS; Wei AH; Kaoma T; Marine JC; Récher C; Stuani L; Joffre C; Sarry JE
    Nat Cancer; 2021 Nov; 2(11):1204-1223. PubMed ID: 35122057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
    Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
    Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia.
    Chakraborty S; Morganti C; Pena BR; Zhang H; Verma D; Zaldana K; Gitego N; Ma F; Aluri S; Pradhan K; Gordon S; Mantzaris I; Goldfinger M; Feldman E; Gritsman K; Shi Y; Hubner S; Qiu YH; Brown BD; Skwarska A; Verma A; Konopleva M; Tabe Y; Gavathiotis E; Colla S; Gollob J; Dey J; Kornblau SM; Koralov SB; Ito K; Shastri A
    bioRxiv; 2024 Aug; ():. PubMed ID: 39211137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
    Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism.
    Hoang DH; Morales C; Rodriguez IR; Valerio M; Guo J; Chen MH; Wu X; Horne D; Gandhi V; Chen LS; Zhang B; Pullarkat V; Rosen ST; Marcucci G; Buettner R; Nguyen LXT
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
    Illangeswaran RSS; Jebanesan DZP; Sivakumar KK; Vidhyadharan RT; Rajamani BM; Janet NB; David E; Velayudhan SR; Mathews V; Balasubramanian P
    Leuk Res; 2023 May; 128():107054. PubMed ID: 36906941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
    Forsberg M; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
    Jiang J; Wang Y; Liu D; Wang X; Zhu Y; Tong J; Chen E; Xue L; Zhao N; Liang T; Zheng C
    Immunotargets Ther; 2023; 12():135-147. PubMed ID: 38026089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
    Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
    Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
    Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
    Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.